Accelrys Announces 2005 Product Launch; Open platform technology to en

    Business Editors
    BIOWIRE2K

    SAN DIEGO--(BUSINESS WIRE)--May 3, 2005--Accelrys, Inc. (NASDAQ:ACCL), today announced the launch of a number of next-generation products across its entire portfolio of software for pharmaceutical, chemical, and materials researchers. Additionally, the company announced its Open Integration Platform, which will integrate Accelrys and SciTegic software in order to enable tailor-made, role-based solutions as well as enhanced intra- and inter-domain productivity.
    In this launch, Accelrys is introducing over 15 enhanced or new products. Among the highlights are new functionality for molecular biologists, new science for computational chemists, and enhanced platform support. These new offerings put Accelrys on the trajectory to deliver integrated product and service solutions that provide customers with a wide choice of new and improved capabilities.
    "The launch of this latest suite of products from Accelrys shows our commitment to delivering new science and tools to our clients, extending the broadest & deepest product portfolio in the industry" said Mark J. Emkjer, president and CEO of Accelrys. "By taking our point-products and identifying toolsets that can enable scientists and engineers in various disciplines, we aim to deliver solutions that address the priority requirements for our clients."

    Extending Discovery Studio

    Accelrys continues to invest in its Discovery Studio (DS) line of products for life science research. This launch includes the latest release of DS GCG-a package of over 100 powerful sequence analysis tools for bioinformaticians. Also included is DS MedChem Explorer, a tool for designing and optimizing lead compounds at the desktop that has now been enhanced with new ADME/Tox models and support for Linux. DS ViewerPro, which provides desktop access to tools for generating, sharing, and analyzing high quality molecular information, now includes a 2D viewing option, as well as an automatic field fitting option for easier superimposition of molecules. DS Accord for Excel, an Excel spreadsheet that allows display and calculation of chemical information, can now retrieve data from Oracle-based Accord Enterprise Informatics products through a simple-to-use data analysis wizard.

    Enhanced Linux Offerings

    QUANTA, Accelrys' leading software environment for X-ray crystallographers also features a Linux port and certification on IBM Thinkpads and IntelliStations running Red Hat Linux. Additionally, a number of new methods and algorithms have been added, including an automated model re-building method that substantially reduces model re-building time.
    Insight II, a molecular modeling and simulation environment for protein modelers, computational chemists and structural biologists now allows seamless integration between Linux and IRIX. Insight II is also certified and optimized on IBM IntelliStations running Red Hat Linux. New science in Insight II includes a new protein-protein docking program called ZDOCKpro.

    Improved Chemistry

    For chemists and screening biologists, Accord Enterprise Informatics (AEI) provides a robust solution for storing and managing drug discovery data. AEI now incorporates a new version of the Accord Chemistry Engine, which includes new calculators, Markush support, and enhanced stereochemistry support.

    New for Materials Science

    Materials Studio (MS) Modeling, Accelrys' suite of modeling and simulation products for computational researchers in chemicals and materials R&D, has a number of important new features and upgrades. New functionality is available for polymer chemists in the form of Blends - which allows calculation of miscibility for binary polymer and solvent systems. MS Modeling now features the first of set of tools derived for the current Accelrys Nanotechnology Consortium, including nano-builders. Platform support has been added for HP Cluster Platform 4000 based on AMD Opteron, HP Cluster Platform 3000 based on Intel Xeon, and the Cluster Platform 6000 based on Intel Itanium 2 processors.

    More Information

    For full details on all the enhancements and new products available, please see http://www.accelrys.com/info/launch/

    About Accelrys

    Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The Company is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/.

    This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward looking statements, including statements regarding the future success of Accelrys products launched in 2005 and of its open integration platform, are subject to risks and uncertainties including, but not limited to, the risk that the platform or products will not be successfully completed or achieve market acceptance, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act, and disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

--30--RJ/la*

CONTACT: Accelrys Ian Clements, 858-799-5440 iclements@accelrys.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: CHEMICALS/PLASTICS PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE PRODUCT SOURCE: Accelrys

Copyright Business Wire 2005